Intro

This chapter explores the potential of GLP-1 receptor agonists in treating neurodegenerative diseases, specifically Parkinson's and Alzheimer's. It emphasizes the mixed results from recent trials, particularly the phase 3 exenatide study, and the importance of critically assessing these findings to shape future research directions.